“In-Bore” MRI-Guided Prostate Biopsy for Prostate Cancer Diagnosis: Results from 140 Consecutive Patients
Open Access
- 1 March 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Urology
- Vol. 14 (1), 22-31
- https://doi.org/10.1159/000499264
Abstract
Objectives: Transrectal ultrasound-guided biopsy (TRUS-GB) is the current reference standard procedure for diagnosis of prostate cancer (PCa) but this procedure has limitations related to the low detection rate (DR) described in the literature. The aim of the study was to evaluate the DR efficiency, and complication rate in a pure “in-bore” magnetic resonance imaging-guided biopsy (MRI-GB) series according to the Prostate Imaging Reporting and Data System, version 2 (PI-RADS v2). Materials and Methods: From July 2015 to April 2018, a series of 142 consecutive patients undergoing MRI-GB were prospectively enrolled. According to the European Society of Urogenital Radiology guidelines, the presence of clinically significant PCa (csPCa) on multiparametric magnetic resonance imaging was defined as equivocal, likely, or highly likely according to a PI-RADS v2, score of 3, 4, or 5, respectively. Results: Of 142 patients, 76 (53.5%) were biopsy naive and 66 (46.5%) had ≤ 1 previous negative set of random TRUS-GB findings. The MRI-GB findings were positive in 75 of 142 patients with a DR of 52.8%. Of the 76 patients with ≤ 1 previous set of TRUS-GB, 43 had PCa found by MRI-GB, with a DR of 57.3%. The DR in the 66 biopsy-naive patients was 48% (32/66). Of the 75 patients with positive biopsy findings, 54 (80.5%) were found to have csPCa on histological examination. Of these 54 patients, 28 had an International Society of Urological Pathology grade 2; 5 had grade 3, 19 had grade 4, and 2 had grade 5. Considering the anatomic distribution of the index lesions using the PI-RADS v2 scheme, the probability of PCa was greater for lesions located in the peripheral zone (55 of 75, 73.3%) than for those in the central zone (20 of 75, 26.7%). Conclusions: Our study conducted on 142 patients confirmed the greater DR of csPCa by MRI-GB, with a very low number of cores needed and a negligible incidence of complications, especially in patients with a previous negative biopsy. MRI-GB is optimal for the diagnosis of anterior and central lesions.Keywords
This publication has 45 references indexed in Scilit:
- Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC Map: A prospective large‐scale cohort studyJournal of Magnetic Resonance Imaging, 2012
- Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imagingBJU International, 2010
- Accuracy of MRI/MRSI‐based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsyNMR in Biomedicine, 2010
- Value of Magnetic Resonance Spectroscopy Imaging and Dynamic Contrast-Enhanced Imaging for Detecting Prostate Cancer Foci in Men With Prior Negative BiopsyClinical Cancer Research, 2010
- Saturation Technique Does Not Decrease Cancer Detection During Followup After Initial Prostate BiopsyJournal of Urology, 2008
- Saturation biopsy for detecting and characterizing prostate cancerBJU International, 2007
- Lesions predictive for prostate cancer in a screened population: First and second screening round findingsThe Prostate, 2004
- Results of the 5 Region Prostate Biopsy Method:Journal of Urology, 2002
- Serial Biopsy Results in Prostate Cancer Screening StudyJournal of Urology, 2002
- PROSPECTIVE EVALUATION OF PROSTATE CANCER DETECTED ON BIOPSIES 1, 2, 3 AND 4: WHEN SHOULD WE STOP?Journal of Urology, 2001